Evidence for the efficacy of immunotherapy in children with high-risk neuroblastoma.

Postepy Hig Med Dosw (Online) 2016 Sep 28;70(0):1001-1004. Epub 2016 Sep 28.

Department of Paediatrics, Nephrology with Dialysis Therapy and Management of Acute Poisoning, Pomeranian Medical University, Szczecin, Poland.

Neuroblastoma is the most common extra-cranial malignancy of childhood, with the highest incidence in children younger than 4 years. The prognosis depends on many factors, such as age at diagnosis, stage of disease and molecular genetic subtype. More than 50% of children who present with the disease are deemed to have high-risk neuroblastoma. The standard therapy for children with high-risk neuroblastoma consists of intensive chemotherapy, surgery, radiotherapy, myeloablative consolidation with autologous haematopoietic stem cell rescue followed by the treatment of minimal residual disease with 13-cis-retinoic acid. Unfortunately, more than half of the patients relapse regardless of the treatment intensity. Combined therapy with monoclonal antibodies (anti-GD2), intravenous interleukin-2 (Il-2), intravenous granulocyte-macrophage colony-stimulating factor (GM-CSF) and oral 13-cis-retinoic acid have been proved to be effective in some randomised trials. A better understanding of the underlying immunological processes in therapy with anti-GD2 antibodies will allow its success to be evaluated more accurately and direct future endeavours. Nevertheless, the long-term benefit of this treatment approach needs to be established.

Download full-text PDF

Source
http://dx.doi.org/10.5604/17322693.1220380DOI Listing
September 2016
2 Reads

Publication Analysis

Top Keywords

high-risk neuroblastoma
12
children high-risk
8
13-cis-retinoic acid
8
autologous haematopoietic
4
underlying immunological
4
consolidation autologous
4
immunological processes
4
myeloablative consolidation
4
haematopoietic stem
4
stem cell
4
treatment minimal
4
better understanding
4
rescue treatment
4
cell rescue
4
understanding underlying
4
processes therapy
4
radiotherapy myeloablative
4
neuroblastoma consists
4
gm-csf oral
4
will allow
4

Similar Publications